Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07478016 · ClinicalTrials.gov registry record

EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients

A clinical trial of Breast Cancer and Ductal Carcinoma In Situ, sponsored by Thomas Jefferson University.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT07478016 is a study of Breast Cancer and Ductal Carcinoma In Situ that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 200 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07478016, a study of Breast Cancer and Ductal Carcinoma In Situ, is actively recruiting participants, sponsored by Thomas Jefferson University.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This is a pilot trial to assess how measures of inflammation are correlated with Social Determinants of Health (SDoH) in breast cancer patients. Expected duration of subject participation is one single time point. The patients will fill out questionnaires and provide a plasma sample.

Interventions

  • OTHER Survey Assessments
  • OTHER Diet Recall
  • OTHER Blood Biomarker Collection

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2022-12-21
Est. Completion 2028-12-31

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT07478016

The ClinicalTrials.gov registry entry for NCT07478016 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Survey Assessments is the first listed.

NCT07478016 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07478016 about?

NCT07478016 is a clinical study titled "EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients". This is a pilot trial to assess how measures of inflammation are correlated with Social Determinants of Health (SDoH) in breast cancer patients. Expected duration of subject participation is one single time point. The patients will fill out questionnaires and provide a plasma sample.

What is the current status of trial NCT07478016?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-12-21. Estimated completion is 2028-12-31.

What conditions does trial NCT07478016 study?

This clinical trial studies the following conditions: Breast Cancer, Ductal Carcinoma In Situ.

What interventions are being tested in trial NCT07478016?

The interventions under investigation include: Survey Assessments (OTHER), Diet Recall (OTHER), Blood Biomarker Collection (OTHER).

Who is sponsoring clinical trial NCT07478016?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07478016 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.